- Home
- ROIV vs CIEN Comparison
ROIV vs CIEN Comparison
Compare ROIV & CIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CIEN
- Stock Information
- Founded
- ROIV 2014
- CIEN 1992
- Country
- ROIV United Kingdom
- CIEN United States
- Employees
- ROIV N/A
- CIEN N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CIEN Telecommunications Equipment
- Sector
- ROIV Health Care
- CIEN Utilities
- Exchange
- ROIV Nasdaq
- CIEN Nasdaq
- Market Cap
- ROIV 8.4B
- CIEN 8.4B
- IPO Year
- ROIV N/A
- CIEN 1997
- Fundamental
- Price
- ROIV $10.91
- CIEN $79.92
- Analyst Decision
- ROIV Buy
- CIEN Buy
- Analyst Count
- ROIV 4
- CIEN 13
- Target Price
- ROIV $17.50
- CIEN $78.62
- AVG Volume (30 Days)
- ROIV 5.5M
- CIEN 1.4M
- Earning Date
- ROIV 05-29-2025
- CIEN 06-05-2025
- Dividend Yield
- ROIV N/A
- CIEN N/A
- EPS Growth
- ROIV N/A
- CIEN N/A
- EPS
- ROIV N/A
- CIEN 0.55
- Revenue
- ROIV $122,585,000.00
- CIEN $4,049,506,000.00
- Revenue This Year
- ROIV N/A
- CIEN $12.65
- Revenue Next Year
- ROIV N/A
- CIEN $8.89
- P/E Ratio
- ROIV N/A
- CIEN $146.30
- Revenue Growth
- ROIV 140.04
- CIEN N/A
- 52 Week Low
- ROIV $8.73
- CIEN $44.69
- 52 Week High
- ROIV $13.06
- CIEN $101.44
- Technical
- Relative Strength Index (RSI)
- ROIV 52.03
- CIEN 69.15
- Support Level
- ROIV $10.58
- CIEN $79.00
- Resistance Level
- ROIV $11.77
- CIEN $81.34
- Average True Range (ATR)
- ROIV 0.33
- CIEN 2.17
- MACD
- ROIV -0.04
- CIEN 0.54
- Stochastic Oscillator
- ROIV 28.57
- CIEN 80.16
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CIEN Ciena Corporation
Ciena Corp is a network and technology company. It provides network hardware, software, and services that support the transport, switching, aggregation, service delivery, and management of video, data, and voice traffic on communications networks. It serves various industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises world-wide. The business activities function through Networking Platforms which generates maximum revenue; Platform Software and Services; Blue Planet Automation Software, and Global Services segments. Geographically, the company derives a majority of its revenue from the Americas, and the rest from the Asia-Pacific (APAC), and Europe, Middle East, and Africa (EMEA) region.